Literature DB >> 12106508

Debate: the argument for. Should every STD clinic patient be considered for type-specific serological screening for HSV?

David M Patrick1, Deborah Money.   

Abstract

The arguments against screening for all individuals attending sexually transmitted disease and genitourinary medicine clinics for herpes simplex virus may seem compelling, but an examination of the facts indicate that the case in favour is strong. While no screening test is perfect, testing can confirm the diagnosis, improve management, help to reduce the risk of transmission - including to the newborn - and assist in the development of public health strategies. Not least, patients want to know whether or not they are infected. In this article we look at the arguments in favour of screening.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12106508

Source DB:  PubMed          Journal:  Herpes        ISSN: 0969-7667


  5 in total

1.  Testing for asymptomatic herpes simplex virus type 2: implications for pretest and post-test counseling.

Authors:  Noreen A Hynes
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

2.  Herpes simplex virus type-specific serology: Where does it fit in the diagnostic armamentarium?

Authors:  Todd F Hatchette
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-07       Impact factor: 2.471

Review 3.  Psychological symptoms associated with genital herpes virus infections: epidemiology and approaches to management.

Authors:  Adrian Mindel; Caron Marks
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection.

Authors:  S L Rosenthal; G D Zimet; J S Leichliter; L R Stanberry; K H Fife; W Tu; D I Bernstein
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

5.  HSV type specific serology in sexual health clinics: use, benefits, and who gets tested.

Authors:  B Song; D E Dwyer; A Mindel
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.